Sobi's soaring revenues beat estimates

Swedish Orphan Biovitrum (STO: SOBI), the Nordic biotech company known as Sobi, has published a financial summary for the fourth quarter and 2018 as a whole that paints a picture of rapid growth.

Revenue at the company was 2.57 billion Swedish kronor ($280 million) for the fourth quarter, growing 37% on the same period of 2017, while the full-year sales figure was 9.14 billion kronor, a 40% jump.

Earnings before interest, tax and amortization (EBITA) for the quarter hit 916 million kronor, up 48% and beating analyst estimates of 831 million kronor.